Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KRAS is a small GTPase that acts as a molecular switch in cell signaling pathways, particularly the RAS/MAPK pathway. It regulates cell proliferation, differentiation, and survival by cycling between an inactive GDP-bound state and an active GTP-bound state. Mutations in KRAS, especially at codons 12, 13, and 61, are common in various cancers and often lead to constitutive activation of the protein, driving uncontrolled cell growth. Direct targeting of KRAS has been historically challenging, but covalent inhibitors for specific mutants like KRAS(G12C) have been developed. Newer approaches include allosteric inhibitors and PROTACs.
Inhibition of GTP binding or downstream signaling of KRAS.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanosine triphosphatase Kirsten rat sarcoma viral oncogene homolog (KRAS).